Novo Nordisk: The Hundred-Year Overnight Success

In 2023 and 2024, a Danish drugmaker most people had never heard of became, briefly, the most valuable company in all of Europe, propelled by two drugs, Ozempic and Wegovy, whose names entered the global conversation almost overnight, medicines that did something no pill ever had: they made people, on a vast scale, lose weight.

It looked like an overnight sensation. It was nothing of the kind. The drugs that conquered the world in the 2020s were the product of a hundred years of patient, unglamorous, foundation-funded work on a single, narrow problem, and of a long, lonely scientific bet that the company nearly abandoned. And then, almost as quickly as it rose, the company stumbled, not because its drugs stopped working, but because a rival made a better one, and the market that had crowned it king cut its value by nearly two-thirds.

The story begins not with weight loss but with insulin, and with a Danish scientist whose wife was dying. In 1921, researchers in Toronto discovered that insulin could treat diabetes, then a death sentence. A Danish Nobel laureate named August Krogh, whose wife was a physician with diabetes, secured permission to bring the process to Denmark, and in 1923, with a diabetes specialist and a pharmacist, founded a laboratory to manufacture insulin. Two years later, two brothers who had worked there split off to found a rival Danish insulin company. For more than sixty years, these two firms, Nordisk and Novo, competed as the great Danish insulin houses, until, in 1989, they merged into a single company: Novo Nordisk.

This long heritage matters, because it made Novo Nordisk something rare: a company with a hundred-year, single-minded obsession with one narrow corner of medicine, the treatment of diabetes and the metabolic system. While the giant American and Swiss pharmaceutical companies chased dozens of diseases, Novo stayed focused, accumulating, decade upon decade, a depth of expertise in metabolic science and in the fiendishly difficult manufacturing of protein-based drugs that few could match. That manufacturing heritage would prove decisive seventy years later. Insulin, and later the GLP-1 drugs, are not simple chemicals synthesized in a vat; they are large, fragile protein and peptide molecules, grown and purified through painstaking biological processes that take years to master and enormous, specialized factories to scale. When the world suddenly demanded hundreds of millions of doses of semaglutide, that century of accumulated manufacturing know-how became a moat in its own right, because a rival cannot simply decide to make a competing peptide drug at scale; it must first acquire, over many years and at vast expense, the very capability Novo had spent its entire existence building.

The Structure That Bought Patience

That patience was made possible by an ownership structure almost unique among the world’s great companies. Novo Nordisk is not controlled by ordinary shareholders chasing the next quarter. It is controlled, through a holding company, by the Novo Nordisk Foundation, a charitable foundation whose mission is to advance science and human health and whose enormous wealth funds research and humanitarian causes around the world. The foundation holds the majority of the voting power, which means that no activist investor, no hostile acquirer, and no panic in the stock market can force the company’s hand.

This structure had concrete consequences. In 2004, when management contemplated selling the company to a larger pharmaceutical group, the foundation blocked the deal, preserving Novo’s independence. And, more importantly, it gave the company the freedom to make bets on a time horizon that a normal public company, terrified of its quarterly earnings, could never tolerate. The scale of what this created is genuinely strange: the very success of Ozempic and Wegovy has made the controlling foundation one of the wealthiest charitable foundations on the planet, its resources directed by charter toward scientific research and human health. The immense profits of the obesity drugs do not flow primarily to private shareholders seeking to maximize their wealth; a controlling share flows, ultimately, toward funding more science, a model in which commercial triumph and humanitarian mission are not in tension but fused.

The Lonely Bet on GLP-1

In the 1990s, a Novo scientist named Lotte Bjerre Knudsen became fascinated by a class of natural hormones called GLP-1, which the body releases after eating, signaling fullness and prompting the release of insulin. The idea of turning these hormones into a drug was scientifically daunting and commercially unproven, and within the company there was pressure, at times, to abandon the research as a costly long shot. It was the kind of speculative, multi-decade scientific bet that a company answerable to impatient shareholders would very likely have killed. But Novo, with its foundation backing and its century-deep commitment to metabolic science, kept funding it.

The Overnight Sensation, a Hundred Years in the Making

What followed was one of the most explosive growth stories in the history of medicine. Ozempic and Wegovy became cultural phenomena, their names ubiquitous, their drugs so in demand that Novo could not make them fast enough and shortages spread around the globe. Ozempic became one of the best-selling drugs on Earth, with sales surging past eighteen billion dollars a year. Novo’s revenues and profits soared, its stock rose more than tenfold over a few years, its American shares climbing past a hundred and forty dollars at the height, and in 2023 and 2024 the once-obscure Danish company briefly became the most valuable company in all of Europe, its market value swelling past six hundred billion dollars. A hundred years of patient, narrow, foundation-funded focus had produced what looked, to the world, like an overnight miracle.

It is worth pausing on what the moat actually was, because it was layered. There was the intellectual property, the patents protecting semaglutide. There was the brand: Ozempic and Wegovy had become household names, a rare and powerful thing for a prescription drug. And there was the genuinely hard, underappreciated science of manufacturing, because making these complex peptide drugs at the colossal scale the world suddenly demanded is an enormous industrial challenge that cannot be replicated quickly. For a few years, Novo Nordisk looked unassailable.

The Rival Who Simply Did It Better

And then came the fall, and its cause is one of the most important lessons in business. Novo was not undone by a scandal, a failed drug, or a financial crisis. It was undone by a competitor who made a better product.

The rival was Eli Lilly, the American pharmaceutical giant which, like Novo, had begun a century earlier as an insulin maker. Lilly had developed its own metabolic drug, tirzepatide, which worked on two gut hormones rather than one, and it launched it as Mounjaro for diabetes and Zepbound for obesity. The scientific distinction mattered: where Novo’s semaglutide acted on a single hormone pathway, Lilly’s molecule acted on two at once, a dual mechanism that, in practice, drove greater weight loss. And in head-to-head clinical trials, the verdict was clear and devastating for Novo: in a direct comparison reported in late 2024, patients lost meaningfully more weight on Lilly’s drug than on Novo’s. By early 2025, the prescription data confirmed it; Lilly’s Zepbound was overtaking Novo’s Wegovy in the United States. Then Lilly unveiled impressive results for an obesity drug in pill form, news that added something like a hundred billion dollars to Lilly’s market value in a stroke, while Novo’s own efforts to improve on semaglutide disappointed investors when the results underwhelmed. Add the cheap compounded copies that flooded the market during the shortages, the looming expiration of key patents, and a leadership shake-up that saw its long-serving chief executive depart, and the result was a collapse. Novo Nordisk’s stock fell roughly sixty-five percent from its peak, erasing hundreds of billions of dollars in value, even as the company remained large and profitable. The king of the GLP-1 era had been dethroned, not by failure, but by a rival’s superior molecule.

The Decision a Dethroned Leader Faces

What Everyone Got Wrong

Novo Nordisk was misjudged at both the top and the bottom of its arc.

Mistake #1: “Ozempic and Wegovy were an overnight sensation.” Reality: They were the product of a hundred years of focus and a decades-long, nearly-abandoned scientific bet.

Mistake #2: “GLP-1 was a speculative long shot not worth funding.” Reality: That patient bet produced one of the most important drug classes in a generation.

Mistake #3: “The dominant, first-mover drug is safe.” Reality: A rival who simply made a more effective molecule took the lead and cut Novo’s value by two-thirds.

Mistake #4: “A near-monopoly on a blockbuster is a low-risk business.” Reality: Concentration in a single drug class cut violently both ways, up on the boom and down on the rival.

The Honest Present

The framework demands honesty about the present, and the present is a still-formidable company humbled from a euphoric peak. Novo Nordisk in 2026 remains one of the two dominant forces in the most important new drug class in a generation, the leading provider of diabetes care in the world, hugely profitable, backed by a foundation that ensures it can think in decades, and armed with a new oral version of its blockbuster. These are real and enduring strengths.

But it has lost its lead in weight-loss efficacy to Eli Lilly, its growth has slowed and it has guided for a difficult year, its stock trades far below its peak, and the patent cliff that will eventually open its blockbusters to cheaper competition looms a few years out. The bull case is that the obesity market is so vast that even a strong number two will prosper enormously, and that Novo’s pipeline and patient structure will let it fight back; the bear case is that it has permanently ceded the lead and faces erosion from competition and patent loss. The hundred-year overnight success has had its first taste of the thing it avoided for a century: a rival who is, for now, simply better.

Why This Matters to Investors

Novo Nordisk offers an investor several durable lessons. The first is the power of focus: a hundred-year commitment to one narrow domain produced a depth of expertise that yielded a world-changing drug. The second is the danger of concentration: the same single-product story that drove a tenfold rise drove a ~65% fall, and one must always ask what happens to a dominant company if its one great product is surpassed, a near-certainty in pharmaceuticals with patents and competition. And the third is the value of patient, mission-aligned ownership, which let Novo fund a long-shot bet that a quarter-driven company would have killed. Studying Novo trains an investor to respect deep focus, to fear concentration even in a winner, and to understand how ownership structure shapes what a company can become. None of this is investment advice.

Lessons in Order of Depth

On the surface: the Method

There is extraordinary power in focus and patience. Novo Nordisk did not chase every disease; it committed, for a hundred years, to one narrow domain, metabolic medicine, accumulating a depth of scientific and manufacturing expertise that a diversified competitor could not match, and that depth is what let it produce a world-changing drug. Deep, sustained focus on a single domain often beats broad diversification, mastery compounds over time in ways that dabbling never can, and the patient accumulation of expertise in one hard thing is itself a formidable and underrated competitive advantage.

Below the surface: the Money

Novo Nordisk is a vivid lesson in the danger of concentration. Its astonishing rise and its brutal fall were both driven by the same thing: its fortunes were tied overwhelmingly to a single class of drug. When semaglutide was ascendant, the concentration produced spectacular gains; when a rival’s molecule pulled ahead, the same concentration produced a devastating fall. A company, or a portfolio, dependent on a single product or theme is exposed to violent swings in both directions, and one must always ask, of any dominant company, what happens if its one great product is surpassed, because in pharmaceuticals, with patents and competition, that surpassing is not a possibility but an eventual certainty.

Below that: the Mind

Novo’s defining triumph rested on a psychological quality rarer than genius: the willingness to fund a lonely, unglamorous, long-shot bet through years of doubt. The GLP-1 research that produced Ozempic and Wegovy was, for a long time, a speculative line of inquiry that faced internal pressure to be killed, the kind of patient, uncertain, decades-long bet that the quarterly logic of most public companies cannot abide. The breakthroughs that change the world are often born from exactly this kind of patient conviction, the discipline to keep funding a promising but unproven idea through the long, doubtful middle is one of the rarest and most valuable traits an institution can possess, and the structures that protect long-term bets from short-term pressure are quietly among the most important determinants of who produces the future.

At the deepest level: the question it leaves us

Novo Nordisk forces us to think about what a company is ultimately for, because its unusual structure embodies an answer most of capitalism has abandoned. It is controlled not by shareholders seeking to maximize their returns but by a foundation whose purpose is to advance human health, with its profits flowing toward science and humanitarian causes, and that structure is precisely what gave it the patience to make the bet that produced a medicine now improving and extending millions of lives. The deepest question Novo leaves us is whether the relentless, short-term, shareholder-first logic that governs most of the corporate world is actually the best way to produce the things that matter most, or whether the patient, mission-aligned, foundation-backed model that produced Ozempic points to something we have lost; and whether the greatest and most beneficial achievements of business, the cures, the breakthroughs, the things that genuinely improve the human condition, are most likely to come not from the companies most ruthlessly devoted to profit, but from the rarer ones patient and purposeful enough to spend a hundred years on a single, stubborn hope.

The Legendary Scorecard

Eight fixed categories, each scored out of ten. The overall is an editorial verdict, a judgment, and explicitly not a weighted average.

Category	Score	Note
Founder Vision	8	A century of disciplined focus on metabolic medicine, rooted in insulin
Innovation	9	Semaglutide is one of the most consequential drugs of the era
Execution	7	Brilliant for years, then out-innovated by Eli Lilly and tripped by pipeline misses
Moat	8	Patents, household-name brands, and hard-to-replicate peptide manufacturing, but contested
Capital Allocation	8	Foundation-backed patience funded the bet that built the franchise
Wealth Creation	9	A 10x+ rise made it Europe’s most valuable company, even after a ~65% fall
Durability	7	Strong, but exposed to a superior rival and a looming patent cliff
Historical Importance	9	Transformed the treatment of diabetes and obesity for the world
Overall Legendary	8.0	Editorial verdict: a patient, world-changing innovator, humbled by a better molecule

At a Glance

The Novo Nordisk Timeline

• 1921: Insulin is discovered in Toronto.
• 1923: Danish Nobel laureate August Krogh and colleagues found Nordisk Insulinlaboratorium to make insulin.
• 1925: The Pedersen brothers found rival Novo Terapeutisk Laboratorium.
• 1989: The two Danish insulin rivals merge to form Novo Nordisk.
• 1990s-2000s: Novo patiently funds GLP-1 research despite internal doubts.
• 2010-2014: Liraglutide reaches market as Victoza (diabetes) and Saxenda (obesity).
• 2018-2021: Semaglutide launches as Ozempic (diabetes) and Wegovy (obesity), with unprecedented weight-loss efficacy.
• 2023-2024: The GLP-1 boom makes Novo briefly Europe’s most valuable company.
• 2024-2025: Eli Lilly’s more effective tirzepatide takes share and Novo’s stock falls sharply.
• 2026: Novo launches an oral GLP-1 pill and fights to regain momentum, valued around $170-210 billion.

Key Numbers

Related Reading

Novo Nordisk is best read beside Coca-Cola, the master of the consumer brand moat, whose lesson in the power of a household name illuminates how Ozempic and Wegovy became cultural phenomena. Read it with ASML, another science-and-IP-driven near-monopoly, whose contrast is instructive, ASML defended its lead where Novo lost its edge, and with Berkshire Hathaway, whose permanent-capital, ignore-the-quarter philosophy echoes the patient, foundation-backed ownership that let Novo make its long bet. For the underlying principle, visit our hub on patent and brand moats and the risks of single-product concentration.

Go Deeper

The Complete Trader’s Edge book builds the full Mind, Method, and Money framework that turns stories like this into a repeatable way of reading any company. Novo Nordisk teaches you to respect deep focus and patient ownership while fearing concentration even in a dominant winner; the book teaches you the discipline to act on both.

This article is part of the Greatest Companies series, adapted from the book Greatest Companies, now available on Kindle.

Frequently Asked Questions

How old is Novo Nordisk, and where did it come from?

Its roots go back to 1923, when Danish Nobel laureate August Krogh and colleagues founded Nordisk Insulinlaboratorium to make insulin, soon followed by a rival Danish insulin company, Novo, founded in 1925. The two competed for decades and merged in 1989 to form Novo Nordisk. The company has focused on diabetes and metabolic medicine for over a century.

What are Ozempic and Wegovy, and why did they make Novo so valuable?

Both are brand names for semaglutide, a GLP-1 drug: Ozempic is approved for diabetes (2018) and Wegovy for obesity (2021). Semaglutide produces dramatic weight loss, 15% or more, with a weekly injection, the first drug to do so safely at scale. The explosive demand made Novo’s revenues and stock soar, and in 2023-2024 it briefly became the most valuable company in Europe, worth over $600 billion.

Why did Novo Nordisk’s stock fall so much?

Primarily because a rival made a better drug. Eli Lilly’s tirzepatide (Mounjaro and Zepbound) produced more weight loss than Novo’s semaglutide in head-to-head trials, and by 2025 was taking prescription share. Lilly’s promising obesity pill, Novo’s disappointing pipeline, competition from cheap compounded copies, a leadership change, and a looming patent cliff all added to a decline of roughly 65% from the 2024 peak.

What is unusual about who owns Novo Nordisk?

It is controlled by the Novo Nordisk Foundation, a charitable foundation whose mission is to advance science and human health, which holds majority voting power through a holding company. This means the company is largely insulated from short-term shareholder and takeover pressure, which gave it the patience to fund the decades-long GLP-1 research that produced its blockbuster drugs.

Is Novo Nordisk still a strong company in 2026?

Yes, though humbled. It remains one of the two dominant players in the GLP-1 market, the world’s leading diabetes-care provider, and highly profitable, and in 2026 it launched the first GLP-1 pill for obesity to fight back. But it has lost the weight-loss efficacy lead to Eli Lilly, its growth has slowed with guidance for a difficult year, and a patent cliff looms around 2032. None of this is investment advice.